https://www.selleckchem.com/pr....oducts/dabrafenib-gs
Further studies are ongoing to investigate this novel drug delivery system in other disease states. PDS is a novel drug delivery platform for the treatment of retinal diseases. Currently, the data from the PDS has shown promising efficacy and ability to substantially mitigate treatment burden while effectively generating visual and anatomic outcomes similar to those in patients receiving the standard monthly ranibizumab for neovascular age-related macular degeneration. Further studies are ongoing to investigate this novel
Like
Comment
Share
